Drug intelligence / Profile preview

xiongzhi tongluo

Development stage: Unknown
Lead developer: Hebei Yiling Hospital
Administration: Oral

Overview

Xiongzhi Tongluo is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of diabetic kidney disease (DKD) and type 2 diabetes mellitus. Developed by Hebei Yiling Hospital, the drug is based on the "collateral disease" (Luobing) theory, which suggests that microvascular complications in diabetes arise from the obstruction of the body's collaterals. The formulation, typically administered as a capsule, aims to improve renal microcirculation, reduce inflammation, and mitigate fibrosis by "dredging the collaterals." It is currently being evaluated in clinical trials to assess its efficacy in reducing proteinuria and slowing the progression of kidney damage in patients with type 2 diabetes.

Brand names: Xiongzhi Tongluo Capsule
Other names: Xiongzhi Tongluo CapsuleXiongzhi Tongluo

Beyond the preview

Go deeper on xiongzhi tongluo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xiongzhi tongluo.

Explore the full profile